✦ LIBER ✦

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

✍ Scribed by Ole Faergeman; Ingar Holme; Rana Fayyad; Sonal Bhatia; Scott M. Grundy; John J.P. Kastelein; John C. LaRosa; Mogens Lytken Larsen; Christina Lindahl; Anders G. Olsson; Matti J. Tikkanen; David D. Waters; Terje R. Pedersen

Book ID: 113445930
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 471 KB
Volume: 104
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2009.04.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of Smoking on Cardiovascular Even

Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)

✍ Paul Frey; David D. Waters; David A. DeMicco; Andrei Breazna; Larry Samuels; And 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 475 KB

Congestive heart failure is associated w

Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease: Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)

✍ Ingar Holme; Timo E. Strandberg; Ole Faergeman; John J.P. Kastelein; Anders G. O 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Comparison of Efficacy and Safety of Ato

Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)

✍ Matti J. Tikkanen; Ingar Holme; Nilo B. Cater; Michael Szarek; Ole Faergeman; Jo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 205 KB

Cardiovascular outcomes and their relati

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial

✍ I. Holme; R. Fayyad; O. Faergeman; J. J. P. Kastelein; A. G. Olsson; M. J. Tikka 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB